No Data
No Data
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Does Apellis Pharmaceuticals (NASDAQ:APLS) Have A Healthy Balance Sheet?
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $39
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
No Data
No Data
EZ_money OP : majority at buy rating
102327823 : india confirmed first case of mpox clade 1b
EZ_money OP 102327823 : interesting